Almirall and BioFocus enter research alliance

Three-year integrated drug discovery alliance is for identifying drug development candidates for treating respiratory disease

26-Jan-2012 - Spain

Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.

The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.  Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort.  The value of this collaboration to BioFocus could reach €7.5 million.

“We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” said Dr. Bertil Lindmark, CSO, Executive Director R&D of Almirall.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances